(Q46941702)

26 December 2017

title

Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma (English)

1 reference

26 December 2017

0 references

Robert J Amato

1

1 reference

26 December 2017

Margaret Morgan

series ordinal

2

1 reference

26 December 2017

Anish Rawat

series ordinal

3

1 reference

26 December 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

26 December 2017

published in

Cancer

1 reference

26 December 2017

volume

106

1 reference

26 December 2017

issue

7

1 reference

26 December 2017

page(s)

1498-1506

1 reference

26 December 2017

Adult renal epithelial neoplasms

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

21 January 2018

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Molecular differential pathology of renal cell tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Histopathology and molecular genetics of renal tumors toward unification of a classification system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Thalidomide: an antineoplastic agent

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Molecular-based therapies for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Immunotherapy of metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Therapeutic options in the management of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.21737

1 reference

7 January 2021

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Current role of thalidomide in cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Phase II trial of thalidomide for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Phase II trial of thalidomide in renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

The treatment of advanced renal cell cancer with high-dose oral thalidomide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

When will melanoma vaccines be proven effective?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Thalidomide therapy for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Interleukin-2: inception, impact, and implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21737

7 January 2021

Identifiers

DOI

10.1002/CNCR.21737

1 reference

26 December 2017

1 reference

26 December 2017